Plain-English translation of NCT06935370 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a new medication, works better when combined with (a medication already used for heart failure) compared to alone. The study will enroll about 4,200 adults with chronic heart failure and a weakened left heart pump. Researchers will track how the medication affects your symptoms, hospital visits, and overall health over time.
Heart failure is a serious condition where the heart doesn't pump blood effectively, and doctors are always looking for better ways to help patients feel better and stay out of the hospital. This trial aims to see whether adding this new treatment to standard care can improve outcomes for people with this type of heart failure.
You likely qualify if…
You likely don't qualify if…
You would take a tablet once daily for between 6 months and about 3.5 years—either the new medication combined with , or a placebo combined with (you won't know which one you're taking). You'll visit the study site regularly for check-ups and blood tests, answer questions about how you're feeling, and doctors will track any changes in your heart failure symptoms, hospitalizations, or other health events. You can continue all your regular heart failure treatments during the study.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States